Relmada Therapeutics Inc

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Relmada Therapeutics addresses setbacks, remains confident in REL-1017's potential

Relmada Therapeutics faced challenges in Q4 2022 with study results, leading to increased expenses and a net loss. Despite setbacks, the company remains confident in REL-1017's potential and is focused on refining trial protocols for future success.

Relmada Therapeutics reports positive Q1 results and advances MDD treatment

Relmada Therapeutics Inc. demonstrates financial improvement and progress in its REL-1017 program for major depressive disorder. The company's strategic amendments to study protocols and upcoming safety study data release indicate a commitment to advancing its pipeline. Addressing challenges in trial management and regulatory interactions is key to sustaining growth and market success.

Relmada Therapeutics reports improved Q2 financials and advances in key trials

Relmada Therapeutics showcased improved financial performance and progress in key clinical trials during the Q2 2023 Earnings Call.
While challenges like enrollment progress and regulatory feedback exist, the company's adaptability and cash position provide strengths to navigate them.
Opportunities lie in expanding the clinical program, achieving positive trial outcomes, and enhancing investor confidence through transparent communication.

Relmada Therapeutics reports positive Q3 results and advances key programs

Relmada Therapeutics demonstrated strong performance in Q3 2023 with progress in key programs and improved financial metrics.
While facing challenges in expense management and trial timelines, the company's strengths in research and financial discipline position them well for future growth.
Opportunities lie in leveraging positive trial results, attracting investors, and advancing innovative treatments to drive value creation.

Relmada Therapeutics reports progress in Phase III programs and financial stability

Relmada Therapeutics Inc showcased positive performance in its Phase III program and financial results, demonstrating resilience and strategic planning. While challenges exist in enrollment and monitoring, the company's confidence in its products and innovative approach to psilocybin present promising opportunities for growth and development.

Relmada Therapeutics Inc reports strong Q1 performance and pipeline advancements

Relmada Therapeutics Inc reported positive financial performance, progress in key programs, and proactive pipeline expansion in Q1 2024, positioning the company for future growth.
While facing challenges such as increased screening failure rates and competition, Relmada's strategic focus on trial optimization and therapeutic innovation presents opportunities for advancement.
The company's commitment to addressing mental health needs through Phase III trials and novel programs like psilocybin underscores its dedication to driving clinical progress and market differentiation.
With a strong financial position and promising developments in the pipeline, Relmada is poised to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Relmada Therapeutics advances CNS disorder treatments amidst financial stability

Relmada Therapeutics is making strides in advancing treatments for CNS disorders, with a focus on major depressive disorder. Financially, the company is managing expenses while progressing key programs. Uncertainty around interim analysis outcomes presents challenges, but successful results could open doors to new opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

NEW YORK, May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present a...

Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

NEW YORK, May 26, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Molly Harper as Executive Vice President of Operations. Ms....

Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations

Should investors be excited or concerned about Relmada Therapeutics' attempt to treat severe depression with a variant of methadone?

Could Opioids Treat Depression? This Biotech Plans to Find Out

Gilead Sciences

Trulieve Cannabis Corp.

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2.

Top Pharmaceutical Stocks for Q2 2020

Relmada Therapeutics: A Promising Depression Focused Player For 2020

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1.

Top Pharmaceutical Stocks for Q1 2020

Relmada Therapeutics Inc. shares RLMD, +141.79% soared 137% Tuesday, after the clinical-stage biotech reported positive results from a midstage trial of a treatment for depression.

Relmada Therapeutics stock rockets 137% on positive trial of depression treatment

News for Relmada Therapeutics Inc Stock (RLMD)